REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Cyclopentanohydrophenanthrene Ring System Doai > Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System > Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System > Modified C-ring (except Methyl In 13-position) (e.g., Double Bond Containing, Substituted, Etc.) Modified C-ring (except Methyl In 13-position) (e.g., Double Bond Containing, Substituted, Etc.)Modified C-ring (except Methyl In 13-position) (e.g., Double Bond Containing, Substituted, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/04/07 - 20070004692 - Preparations and therapy of intrathecal inflammatory disease A method for prevention and/or treatment of inflammatory/edematous diseases of the central nervous system or increased intracranial pressure comprises intrathecal administration of at least one anti-inflammatory and/or anti-edematous agent. ... 09/21/06 - 20060211668 - Use of ciclesonide for the treatment of inflammatory bowel diseases The invention relates to the novel use of ciclesonide in the treatment of inflammatory bowel disease. ... 09/14/06 - 20060205704 - Modulation of neurodegenerative diseases through the progesterone receptor Methods for modulating hormonal pathways involving the progesterone receptor in a subject with a neurodegenerative disorder, are provided. Progesterone receptor activity is modulated by administering an effective amount of an progesterone receptor modulating pharmacological agent to a subject such that the progesterone receptor modulating pharmacological agent interacts with the progesterone ... 07/13/06 - 20060154910 - Use of steroids to treat ocular disorders Methods and compositions for treating retinal edema and NPDR are disclosed. ... 07/06/06 - 20060148775 - Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation. ... 06/01/06 - 20060116359 - 17.beta-(alpha-hydroxy)-esters of androstanes as intermediates for the preparation of 17.beta-fluorinated-androstane esters Process for the preparation of polyhalogenated steroids, in particular of androstanic fluoro derivatives corticosteroids by means of the formation of new androstanic S-hydroxy alkyl or aralkyl-17-carbothioate intermediates. ... 05/04/06 - 20060094700 - Heat sterilization of a steroid in the presence of phosphate A process for sterilizing a water-insoluble steroid composition comprising heat sterilizing the steroid in the presence of phosphate is disclosed herein. Compositions related thereto are also disclosed. ... 04/06/06 - 20060074061 - Formulations of glucocorticoids to treat pathologic ocular angiogenesis Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema ... 03/23/06 - 20060063749 - Pharmaceutical compositions and treatment methods - 5 The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of ... 03/23/06 - 20060063748 - Methods for treating psychosis associated with interferson-alpha therapy The present invention relates to the treatment of psychosis associated with interferon-therapy. The present invention further relates to kits for the treatment of Hepatitis C in a patient. ... 03/16/06 - 20060058277 - Use of oculosurface selective glucocorticoid in the treatment of dry eye Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of ... 03/09/06 - 20060052354 - Methods for treating migraine This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating migraine in a subject. ... 01/26/06 - 20060019937 - Novel crystalline forms of 6alpha, 9alpha -difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene 17beta-carboxylic acid and processes for preparation thereof Novel crystalline forms II, III, IV, V, VI, VII and VIII of 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxyandrosta-1,4-diene-17β-carboxylic acid, a chemical intermediate useful in the preparation of fluticasone propionate, and novel methods of making these forms, substantially free of water, are disclosed. ... 01/26/06 - 20060019936 - Methods and compositions for treating cancer The invention provides compounds and methods for treating cancer. Exemplary compounds are multi-functional compounds with two different moieties connected by a linker. Compounds of the invention can activate one or more pathways that result in the inhibition of cell growth. The invention includes cytostatic and cytotoxic compounds. Methods and compositions ... 01/12/06 - 20060009436 - 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations The invention relates to 17α-alkyl-17β-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to 17-oxo-estra-1,3,5(10)-trienes as well as 17β-hydroxy-estra-1,3,5(10)-trienes as intermediate products in the production of the estratrienes according to the invention. The invention also relates to the use of 17α-alkyl-17β-oxy-estratrienes for the ... 01/12/06 - 20060009435 - Synthesis and powder preparation of fluticasone propionate An improved process for preparing fluticasone propionate, performed in the presence of water, is disclosed. Further disclosed is a process for preparing a fluticasone propionate that is highly suitable for administration by inhalation. Further disclosed are fluticasone propionate and a powdered fluticasone propionate prepared by these processes and pharmaceutical compositions ... 12/22/05 - 20050282792 - Calcitriol/clobetasol propionate compositions for the treatment of psoriasis Topically applicable pharmaceutical compositions useful for the treatment of psoriasis contain respective amounts of calcitriol and clobetasol propionate permitting a once-per-day effective regimen of topical application onto the part or parts of the skin affected by psoriasis. ... 12/15/05 - 20050277624 - Use of corticosteroids alone or in conjunction with nutritional therapy to reduce stress in animals The invention provides a method of alleviating the effects of stress in a non-human animal comprising administering a therapeutically effective amount of a corticosteroid, such as dexamethasone, alone or in conjunction with a nutritional supplement, to the animal in need thereof. The corticosteroid can be administered prior to exposure to ... 11/03/05 - 20050245497 - Treatment of ophthalmic conditions The present invention provides a method of treatment of an individual with an ophthalmic condition that may comprise the step of: administering to the individual a therapeutically effective amount of a compound capable of modulating the activity of mineralocorticoid receptors within cells or tissue located in an eye or adjacent ... 10/06/05 - 20050222112 - Use of agonists of the glucocorticosteroid and/or mineralo-corticosteroid receptors, in particular corticosteroids for the treatment of addiction Use of agonists of corticosteroid receptors and/or mineralo-corticoid receptors and an addictive drug or the pharmacodynamic equivalent thereof in the production of a medicament for the therapy of an addictive disease triggered by said addictive drug or connected thereto. ... 10/06/05 - 20050222111 - Method for treating a respiratory disease The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer. ... 10/06/05 - 20050222110 - Use of loteprednol etabonate for the treatment of dry eye Disclosed in embodiments herein is a method of treating moderate to severe dry eye in a patient in need thereof, the method comprising topically administering to the patient Loteprednol etabonate in an ophthalmolically acceptable carrier. ... 10/06/05 - 20050222109 - Crystalline 19-norsteroids The present invention are two crystalline salts, 17α-acetoxy-21-methoxy-11β-(4-,N,N-dimethylaminophenyl)-19 norpregna-4,9-diene-3,20-dione hydrochloride and 17α-acetoxy-21-methoxy-11β-(4-,N,N-dimethylaminophenyl)-19 norpregna-4,9-diene-3,20-dione hydrobromide, of the corresponding free base which is an amorphous solid. ... 10/06/05 - 20050222108 - Solvent-based sterilisation of pharmaceuticals A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier. ... 10/06/05 - 20050222107 - Novel process or a salt thereof with a compound of formula LCH2F wherein L represents leaving group optionally in the presence of a phase transfer catalyst, a water-immiscible non-solvating organic liquid solvent and water is described. ... 09/01/05 - 20050192264 - Slow release steroid composition A pharmaceutically acceptable composition comprising an anti-inflammatory steroid or pharmaceutically acceptable salt thereof, which exists in varying crystal and crystal composite sizes wherein the proportion of crystals and crystal composites above 20 μm in size in the composition is greater than the proportion of crystals and crystal composites under 20 ... 08/11/05 - 20050176694 - Pharmaceutical compounds B=-TB—X2-TBI-, wherein TB is (CO), TBI is O, S, NH, and X2 is a bivalent bridging group; and C is a bivalent radical. ... 06/30/05 - 20050143365 - Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat meningiomas; to treat uterine leiomyomas; ... 06/30/05 - 20050143364 - 21-substituted progesterone derivatives as new antiprogestational agents In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine ... 06/30/05 - 20050143363 - Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases Featured is a methodology for administering a therapeutic medium to the posterior segment of an eye including instilling or disposing the therapeutic medium sub-retinally. In particular embodiments, the therapeutic medium is disposed in a sub retinal space. Such instillation being accomplished by one of injection or implantation of the therapeutic ... ### FreshPatents.com Support |